Li Huashun, Yu Dongyang, Li Lianbing, Xiao Juanjuan, Zhu Yijian, Liu Yi, Mou Li, Tian Yafei, Chen Linbo, Zhu Feng, Duan Qiuhong, Xue Peipei
Department of Pathology, The First People's Hospital of Tianmen, Tianmen, Hubei 431700, China.
Department of Clinic Laboratory, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 431700, China.
J Oncol. 2022 Apr 22;2022:3691635. doi: 10.1155/2022/3691635. eCollection 2022.
Ovarian cancer (OC) is the most fatal gynecologic cancer. The branched-chain -keto acid dehydrogenase kinase (BCKDK) plays an important role in many serious human diseases, including cancers. Its function in promoting cell proliferation and migration has been reported in various cancers. However, the biological role of BCKDK and its molecular mechanisms underlying OC initiation and progression are unclear.
First, the expression level of BCKDK in OC cell lines or tissues was determined using tissue microarray- (TMA-) based immunohistochemistry or western blotting. Then, growth curve analysis, anchorage-independent cell transformation assays, wound healing assays, cell migration assays, and tumor xenografts were used to test whether BCKDK could promote cell transformation or metastasis. Finally, the signaling pathways involved in this process were investigated by western blotting or immunoprecipitation.
We found that the expression of BCKDK was upregulated in OC tissues and the high expression of BCKDK was correlated with an advanced pathological grade in patients. The ectopic overexpression of BCKDK promoted the proliferation and migration of OC cells, and the knockdown of BCKDK with shRNAs inhibited the proliferation and migration of OC ex vivo and . Moreover, BCKDK promoted OC proliferation and migration by activating MEK.
Our results demonstrate that BCKDK promotes OC proliferation and migration by activating the MEK/ERK signaling pathway. Targeting the BCKDK-MEK axis may provide a new therapeutic strategy for treating patients with OC.
卵巢癌(OC)是最致命的妇科癌症。支链α-酮酸脱氢酶激酶(BCKDK)在包括癌症在内的许多严重人类疾病中起重要作用。其在促进细胞增殖和迁移方面的功能已在各种癌症中报道。然而,BCKDK在OC发生和发展中的生物学作用及其分子机制尚不清楚。
首先,使用基于组织微阵列(TMA)的免疫组织化学或蛋白质印迹法测定OC细胞系或组织中BCKDK的表达水平。然后,使用生长曲线分析、非锚定依赖性细胞转化试验、伤口愈合试验、细胞迁移试验和肿瘤异种移植来测试BCKDK是否能促进细胞转化或转移。最后,通过蛋白质印迹或免疫沉淀研究参与该过程的信号通路。
我们发现BCKDK在OC组织中的表达上调,并且BCKDK的高表达与患者的高级别病理分级相关。BCKDK的异位过表达促进了OC细胞的增殖和迁移,而用短发夹RNA(shRNAs)敲低BCKDK在体内外均抑制了OC的增殖和迁移。此外,BCKDK通过激活MEK促进OC的增殖和迁移。
我们的结果表明,BCKDK通过激活MEK/ERK信号通路促进OC的增殖和迁移。靶向BCKDK-MEK轴可能为治疗OC患者提供一种新的治疗策略。